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SUMMARY
Cardiovascular diseases are the leading cause of mortality globally. Cardiac fibrosis is
an essential component of changes that occur in heart’s size, shape, and composition, in
response to cardiac disease or cardiac damage. Exosomes are extracellular vesicles that aid
cell-cell communication and carry proteins, metabolites, nucleic acids, etc. miRNAs are
small non-coding ribonucleic acid (RNA) molecules that can be transported by exosomes
and are uniquely capable of facilitating long-term repair by altering the targeted cells’
transcriptome. Prior studies have demonstrated relationships between exosomal miRNA
content and fibrosis in the heart. In this research, self-built scoring models and PLSR
modeling were used to find miRNAs that can downregulate cardiac fibrosis. miR-21, miR-
33, miR-125b, miR-155-5p, miR-34a were identified as profibrotic miRNAs and miR-29b,
miR-29a, miR-26a, miR-30c, miR-29c were identified as antifibrotic miRNAs. Selected
under-studied miRNAs were also identified that might be important regulators of cardiac
fibrosis. Computational models were built to predict the extent of cardiac fibrosis with
miRNAs’ fold-changes as inputs. A computational workflow was developed to predict the
extent of cardiac fibrosis when exosomes with custom-designed packages of miRNA con-
tent will be injected into animal models. This analysis consolidates relationships between






Cardiac fibrosis is characterized by an imbalance in extracellular matrix (ECM) production
and degradation, resulting in accumulation of proteins in cardiac interstitium, causing car-
diac dysfunction in a wide array of cardiac diseases. Injury to heart can activate fibrotic
responses, distorting heart’s shape and compromising physiological cardiac functions. Car-
diac fibrosis stiffens the heart which causes problems with cardiac cycle by affecting the
contraction and relaxation of the heart during systole and diastole, respectively [1]. In
response to different types of injuries and stimuli, there are two types of cardiac fibrosis
[2]:
1. Replacement/ reparative fibrosis: Ischemia, inflammation, toxic insult, etc. can cause
cardiomyocyte necrosis, inducing replacement of cardiac muscles with fibrous tissue.
2. Reactive fibrosis: Pressure, volume overload, aging, cardiomyopathies, etc. can
cause excessive deposition of ECM in expanded interstitial and perivascular spaces
without significant loss of cardiomyocytes.
Cardiac fibroblasts are involved in the formation of ECM. In response to cardiac injury,
fibroblasts differentiate into myofibroblasts to generate an inflammatory response and pro-
duce high levels of ECM proteins. Collagen is the main structural protein found in the ECM
inside the body and helps in maintaining tissue integrity [3]. Collagen has been shown to
be upregulated in pathological conditions like myocardial infarction, aging and diabetes [4,
5, 6]. Connective Tissue Growth Factor (CTGF) is a cysteine rich protein which is highly
expressed in fetal myocardium. In adult heart, it is only expressed in atria and large blood
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vessels, and its increased expression has been associated with cardiac pathologies [7, 8, 9].
Vimentin protein has been identified as a marker of cardiac fibroblasts, can label them with
high sensitivity and check purity of their isolation. Heart’s fibrotic response to a stimulus
can be divided into three stages [10, 11]:
1. Initiating stage: Stimulus triggers a fibrotic response by increasing profibrotic growth
factors and cytokines inside the myocardium and in circulation.
2. Effective stage: Signaling pathways (like Wnt siganling) and transcriptional factors
(like Smad) are activated when pro-fibrotic growth factors and cytokines bind to
their receptors, ultimately transforming cardiac fibroblasts into myofibroblasts (Fig-
ure 1.1).
3. Amplificative stage: Pro-fibrotic growth factors and cytokines form a positive feed-
back loop, resulting in the amplification of fibrosis.
Figure 1.1: Process of cardiac fibrosis development
During the development of cardiac fibrosis, pathological stimuli cause cardiomyocytes
necrosis and myofibroblasts growth. This leads to ECM remodeling and stiffening of the
heart as shown with the example of fibrotic tissue in the diagram. Image created using
BioRender.com.
Cardiac fibrosis can be measured using non-invasive magnetic resonance techniques
and staining of tissue biopsies. T1 mapping, a cardiac magnetic resonance-based method
has been recently developed for quantifying fibrosis in heart [12]. For histological assess-
ment of fibrosis, extracted tissue can be stained with Masson Trichrome or Picrosirius red
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stain which contain dyes that bind to collagen to give blue and red color, respectively [13,
14]. Other techniques for quantifying cardiac fibrosis include using CNA35, Hydroxypro-
line assay and Sircol assay [15].
Cell death during myocardial infarction initiates phases of reparative fibrosis in which
fibroblasts and myofibroblasts generate a fibrotic scar to replace the damaged tissue [16].
This reparative process is beneficial to prevent the rupturing of ventricular wall, however, it
is followed by reactive fibrosis in uninjured myocardium which causes stiffness in the heart,
hindering normal cardiac functions [17]. Cardiac (atrial) fibrosis causes heterogeneity in
conduction of impulses, contributing to the development of atrial fibrillation [18].
Age related accumulation of ECM in elderly patients causes cardiac dysfunction [5].
Unlike conventional fibrosis, aging associated cardiac fibrosis is caused due to degenera-
tive changes like apoptotic cell death, loss of cardiomyocyte, thereby promoting collagen
deposition [19]. Aging derived continued stress response causes low grade systemic inflam-
mation, resulting in increase of certain cytokines and proteins which have been linked to
fibrosis [20, 21]. Research shows that there is a close relationship between cardiac fibrosis
and hypertension, a common disease among elderly patients [22].
Independent of atherosclerosis or hypertension, diabetic patients have been diagnosed
with perivascular and interstitial fibrosis [23]. Upregulated levels of collagen type III with
increased interstitial myocardial fibrosis has been found in hearts of diabetic patients in
comparison to non-diabetic patients [24]. Without any history of myocardial infarction, re-
placement fibrosis has been observed in diabetic patients [25]. Diabetes has been related to
increased fibrotic responses when coupled with other cardiac conditions like aortic stenosis
[26].
There is ongoing research for better understanding of the mechanisms of cardiac fi-
brosis and for developing its treatment. Histone deacetylases inhibitors have been shown
to inhibit inflammatory cytokines and impede fibroblast signaling during cardiac stresses
like hypertension and myocardial infarction, thus alleviating cardiac fibrosis [27]. Renin-
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angiotensin-aldosterone-system, Transforming growth factor beta (TGF-β) signaling path-
way, injectable biomaterials, Cardiac Progenitor Cell (CPC) transplantation therapy, repro-
gramming of fibroblasts, non-coding RNAs like miRNAs, epigenetic modifiers, etc. are
being explored as potential therapeutic options for cardiac fibrosis [28].
1.2 Stem cells, exosomes, and microRNAs
1.2.1 Stem cells
Stem cells are special cells that have the ability to continuously divide and differentiate into
various cell types. They are capable of proliferating and self-renewing themselves for long
periods of time and have the potential to give rise to specialized cells like cardiomyocytes,
neurons, hepatocytes, etc. As shown in Figure 1.2, based on their potency, stem cells have
been majorly divided into three types:
1. Totipotent stem cells: They can differentiate into all cell types and are found in an
embryo as well as in all extra-embryonic cells (like placenta). For example, cells
from 1-3 days old embryo [29].
2. Pluripotent stem cells: They can differentiate into all cell types in the body. For
example, cells of 5-14 days old blastocyst [30].
3. Multipotent stem cells: They can differentiate into a limited number of cell types in
a particular lineage. For example, adult stem cells and cells found in fetal tissue and
cord blood [31].
Progenitor cells are partially specialized cells that can give rise to particular cell types
and unlike stem cells, can divide only a limited number of times. For example, cardiac
progenitor cells and endothelial progenitor cells.
Stem cells are being increasingly researched to understand disease pathways, generate
healthy cells to replace diseased ones and for testing of new drugs. Stem/progenitor cell-
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Figure 1.2: Classification of stem cells based on sources of origin and differential po-
tentials
Stem cells have been classified based on their source of origin into embryonic stem cells
and adult stem cells, and based on their differential potentials into totipotent stem cells,
pluripotent stem cells, multipotent stem cells, etc. Adult stem cell can be further classified
into mesenchymal stem cell, hematopoietic stem cells, etc.
based therapies can greatly impact the field of regenerative medicine and have attracted
researchers’ attention due to their efficacy in treating diseases in preclinical transplanta-
tion, tissue injury models and human clinical trials [32, 33, 34, 35]. Stem cells have been
classified based on their source and function in Figure 1.2. Many stem/progenitor cells that
can be used to repair organs and improve organ functions are described below:
• CPC: These cells can be isolated from juvenile heart and have the ability to differ-
entiate into cells of three cardiac lineages: cardiomyocytes, smooth muscle cells and
endothelial cells. CPCs have been shown to repair heart and improve its function
post cardiac injury [36, 37].
• Embryonic Stem Cell (ESC): They are derived from the inner cell mass of blasto-
cyst and can renew indefinitely. They can give rise to any of the three embryonic
germ layers- endoderm, mesoderm and ectoderm, and can further differentiate into
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cardiomyocytes, neural tissue, adipocytes, etc. ESCs have been used to improve lo-
comotion post spinal cord injury, in developing cure for Parkinson’s disease and in
attempts of lung regeneration [38, 39, 40, 41, 42].
• Mesenchymal Stem Cell (MSC): These cells can be isolated from many different
sources like bone marrow, muscle, umbilical cord, adipose tissue, etc. and can differ-
entiate into lineages like osteocytes, chondrocytes, monocytes, adipocytes and neu-
rons. Their roles have been investigated in Alzheimer’s disease, multiple sclerosis
and retinal degenerative disease [43, 44, 45, 46].
• Hematopoietic Stem Cell (HSC): These cells can be found inside the bone marrow
and have the potential to regenerate the whole hematopoietic system. There are many
intermediate progenitor cells between HSCs and mature blood cells. Blood disorders
such as leukemia, myeloma and lymphoma require HSC transplantation therapy [47,
48, 49].
Cardiac fibrosis and stem cells
CardioChimeras, synthesized by the fusion of CPCs and MSCs, have been shown to
alleviate fibrosis when injected in the border zone region of an acutely injured mouse heart
[50]. Cellular transplantation of bone marrow derived MSCs have been shown to reduce
fibrosis in porcine myocardial infarction model [51]. Previous research has demonstrated
that MSCs are able to modulate the antifibrotic activity of cardiac fibroblasts, inhibit my-
ocardial fibrosis in rat model of dilated cardiomyopathy, prevent cardiac fibrosis in iso-
proterenol induced global heart failure rat model and reduce myocardial fibrosis in canine
chronic ischemia model [52, 53, 54, 55]. Transplantation of biodegradable and nanofibrous
patches seeded with MSCs into epicardium of infarcted regions attenuated cardiac fibrosis
in a rat model [56].
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1.2.2 Exosomes
Exosomes are 30 to 200 nm diameter long, single-membrane, lipid bilayer extracellular
vesicles. They have roles in protein quality control, driving anterior–posterior cell polarity,
ECM modulation, cell-cell signaling and molecular transfer [57]. As shown in Figure 1.3,
exosome biogenesis takes place through the following three modes:
1. Vesicles bud into discrete endosomes that mature into multivesicular bodies (MVB),
and release exosomes into extracellular space upon plasma membrane fusion [58].
2. Exosomes directly bud from plasma membrane which result in their immediate re-
lease outside the donor cell [59].
3. Vesicles bud into intracellular plasma membrane–connected compartments (IPMCs)
and are then be released by de-constriction of IPMCs’ necks. This mode of biogen-
esis usually results in delayed release of exosomes due to lengths of IPMCs’ necks
[60].
During cell-cell signaling, exosomes transport proteins, lipids, nucleic acids, etc. from
donor cells to recipient cells as shown in Figure 1.3 [61]. Exosomes are involved in inter-
cellular transport and play significant roles in multiple facets of human health and disease,
including development, tissue homeostasis, neurodegenerative diseases and viral invasion
[57].
Exosomes facilitate communication between immune cells and mediate immune sup-
pressive and immune-activating modulation [62]. In brain, exosomes aid cell-cell com-
munication between neurons and other cell types that ultimately supports axon integrity,
microglia and myelination [63]. Changes in exosome number and content has been seen in
cardiovascular diseases where certain proteins and deoxyribonucleic acid (DNA)/RNA are
transferred only under stress conditions like hypoxia [64, 65, 66].
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Figure 1.3: Exosome biogenesis and exosome mediated intercellular transport
Three modes of exosome biogenesis are shown with numbers 1,2, and 3, in correspondence
with the number of modes mentioned in the text above. Exosomes are transporting proteins,
lipids, nucleic acids, etc. from donor cell to recipient cells, aiding in cell-cell signaling.
Image created using BioRender.com.
Along with being responsible for normal physiology, exosomes are also involved in
many pathological conditions. Neurodegenerative diseases like Alzheimer’s disease and
Parkinson’s disease are caused by amyloid plaque formation and increase in aggregation
of α-synuclein, respectively. In Alzheimer’s disease, exosomes spread amyloid-β to other
neuronal cells to form amyloid plaque within the patient’s brain [67]. Parkinson’s disease
progression has been linked to neuroblastoma exosomes which reduce the catalysis of α-
synuclein, leading to an increase in its aggregated levels [68].
In cardiovascular diseases, exosomes are being researched for working as diagnostic
biomarkers and therapeutic agents. Exosome mediated cell-cell communication has been
shown to play a significant role in each phase of atherosclerosis [69, 70]. Prior research has
reported that myocardium can be protected from ischemia/reperfusion injury by using ex-
osomes from human and rat plasma. [71] Inter-cellular signaling using exosomes between
cardiac fibroblasts and cardiomyocytes plays an important role in cardiac hypertrophy and
heart failure [72].
Previous studies have identified roles of exosomes in progression of cancer, tumor, as
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well as investigated their curative functions in these diseases [73, 74, 75]. Exosomes have
been shown to convert benign epithelial cells into malignant cancer cells [73]. Exosome
mediated endocrine and paracrine signaling has been associated with cancer metastasis-
ECM remodeling, indavopodia formation and Epithelial-to-mesenchymal transition (EMT)
[76]. Exosomes may be used as cancer biomarkers in liquid biopsies to aid in the diagnosis
of many cancers, including pancreas, ovarian, prostate and melanoma [77, 78, 79, 80].
Cardiac fibrosis and exosomes
The role of exosomes in mediating cardiac fibrosis is being increasingly explored by
researchers. ESC derived exosomes have been shown to reduce fibrosis when injected in
a myocardial infarction mouse model, improving cardiac function [81]. Exosome medi-
ated paracrine regulation was reported to be the basis of regulation of fibrosis by induced
pluripotent stem cell derived cardiomyocytes [82]. Injection of cardiac stem cell derived
exosomes significantly suppressed cardiac fibrosis in a dilated cardiomyopathy model [83].
Reduction of cardiac fibrosis was observed when human umbilical cord MSC derived ex-
osomes were injected into a myocardial infarction rat model [84]. CPC derived exosomes
have shown improve cardiac function and alleviate fibrosis in a rat model of ischemia-
reperfusion [85]. Exosomes from adipose derived stem cells decreased cardiac fibrosis in a
myocardial infarction rodent model [86].
1.2.3 microRNAs
miRNAs are small non-coding RNA molecules that are 19-24 nucleotides in length and are
capable of post-transcriptional gene silencing, thereby regulating gene expression levels.
One miRNA can influence the expression of hundreds of genes, therefore miRNAs col-
lectively regulate more than half of the protein-coding genes in humans and are involved
in many diseases pathways [87, 88]. They have roles in cell proliferation, differentiation,
death, etc. and their aberrant expression can result in diseased states like cancer, cardiovas-
cular diseases and neurodevelopmental disorders [89].
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Genes coding for miRNAs are present in the DNA within the nucleus of cells. These
genes are transcribed by RNA polymerase II to make messenger RNA (mRNA), which are
called primary miRNA in this case and have a hairpin loop structure [90]. Ribonuclease
(RNase) III endonuclease Drosha as well as its cofactor, DGCR8, attach to the primary
miRNA and cleave ends of the stem of hairpin loop to make precursor miRNA. A trans-
porter molecule Exportin-5 carries the precursor miRNA into the cytoplasm where it is
recognized by a RNase protein called DICER [91]. DICER cleaves the stem loop and
forms the double-stranded miRNA intermediate [92]. Then AGO2 binds to the miRNA,
unwinds it and one strand is selected [93]. Some other proteins combined with this miRNA
and AGO2 form the miRNA induced silencing complex (miRISC) complex. The miRISC
complex is guided by the single-stranded mature miRNA to its target sites for inactivating
genes [94].
The mRNA of the target gene is complementary to the nucleotide sequence of miRNA
so they can bind together. As shown in Figure 1.4, there are two ways in which miRISC
can inactivate the mRNA [95]:
1. In case of partially complementary mRNA, miRISC complex attaches to the target
mRNA which prevents ribosome from binding, inhibiting the translation of mRNA.
2. For perfectly complementary mRNA targets, miRISC complex cleaves the mRNA
and the cleaved mRNA is further degraded by the cell.
As far as nomenclature is concerned, miRNAs are named sequentially. For example,
if a novel miR-231 is discovered, the next novel miRNA discovered will be called miR-
232. The first three letters in the name of miRNA indicates the organism from which the
miRNA has been extracted, for example, hsa-miR-231 is a human miRNA and mmu-miR-
231 is a mouse miRNA. miR-231 with the capital ’R’ refers to the mature form of the
miRNA whereas mir-231 with small ’r’ indicates the miRNA gene and the miRNA primary
transcript’s stem loop. If different precursor sequences mature into same miRNA, they
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Figure 1.4: miRNA gene silencing mechanism
A) Translational repression: miRISC complex binds to partially complementary target site
on mRNA and blocks mRNA’s translation. B) mRNA cleavage: miRISC complex binds
to perfectly complementary target site on mRNA and cleaves mRNA which is further de-
graded by the cell. Image created using BioRender.com.
are named as miR-231-1 and miR-231-2. Closely related mature sequences are designated
by lettered suffixes like miR-231a and miR-231b. When the mature sequence of one out
of the two miRNAs originating from the same precursor miRNA has significantly higher
abundance, it will be called miR-231, whereas the mature miRNA from the opposite arm
will be called miR-231*. If there is no predominant mature miRNA, they are named like
miR-231-5p (from the 5’ arm) and miR-231-3p (from the 3’ arm). These conventions are
followed in most cases but there are a few exceptions like nomenclature of plant and viral
miRNAs [96].
To overexpress or underexpress a miRNA, agomirs or antagomirs can be injected.
Agomirs are double-stranded nucleotide sequences that mimic endogenous miRNAs and
regulate the biological function of the target gene. On the other hand, antagomirs are
single-stranded and designed in a way that they can bind to the mature miRNA, inhibiting
the expression of the endogenous miRNA.
Physiological quantities of miRNA are essential for the normal functioning of the body.
miRNAs have been identified as potential biomarkers of aging, cellular senescence, and
Alzheimer’s disease and can regulate diverse pathways of cellular differentiation, growth,
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and apoptosis [97, 98]. Important roles of miRNAs have been identified in the cardiovascu-
lar system and provided new insights on various cardiac pathologies like hypertrophy, heart
failure, myocardial infarction and atherosclerosis [99]. They also have important functions
in nervous system and its development, and their roles as mediators of plasticity are being
explored [100].
Aberrant expression of miRNA can result in pathological conditions. Neurodegenera-
tive diseases like Alzheimer’s disease is identified by memory loss, cognitive impairments,
and is caused by phosphorylated tau formation, synaptic loss, and amyloid plaque forma-
tion [97]. Dysfunction of miRNAs has been shown to cause hyper phosphorylation of
tau and formation of toxic tau, and overexpression of certain miRNAs has resulted in im-
proved synaptic transmission [101, 102, 103]. Several miRNAs have been associated with
increased production of amyloid-β [104, 105].
Research has confirmed that a variety of cancers are caused by aberrant expression of
miRNAs, with miRNAs functioning as both oncomiRs and tumor suppressors [106]. Dys-
regulation of miRNA biogenesis protein DICER, Drosha and AGO2 have been linked to
the prognosis of cancer patients [107, 108, 109]. Many types of cancers cause downregula-
tion of tumor suppressive miRNA families like miR-34, let-7, miR-520, etc. and owing to
multiple consolidated evidences on the same, some of this research has also progressed to
clinical trials [110, 111, 112, 113]. miRNAs with oncogenic functions like miR-21, miR-
155, miR-210, etc. are also upregulated in cancerous tissue in comparison to healthy tissue
[114, 115, 116].
In heart, miRNAs are dysregulated in response to stress conditions like hypoxia and
restoration of miRNAs to the normal levels post injury have resulted in cardiac healing
[117, 118]. Some miRNAs like miR-765, miR-25, miR-24 are responsible for contractile
regulation, which is a hallmark of heart failure [119, 120, 121]. Age related dysregulation
of miRNAs (miR-1 and miR-133) has also shown to play important roles in problems
related to rhythm of the heartbeat like arrhythmias [122].
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Cardiac fibrosis and microRNAs
Research in the field of miRNA is still in its nascent stages and their relation to cardiac
fibrosis is being increasingly explored. miR-30 and miR-133 have been shown to target
CTGF and collagen expression is influenced by miR-29 activity [123, 124]. Adenoviral
based transport of miR-1 in myocardium in a rat model of pressure overload-induced hy-
pertrophy reduced cardiac fibrosis, thereby improving cardiac function [125]. MSCs trans-
fected with miR-133a decreased cardiac fibrosis in a rat myocardial infarction model more
than MSCs without miR-133a transfection [126]. miRNA families can also regulate cardiac
fibrosis like miR-15 family inhibits TGF-β pathway, affecting cardiac fibrosis [127, 128].
A major challenge with using miRNAs for treating cardiac fibrosis is their multiplicity of
gene targets and their synergistic effect makes it difficult to target specific genes [129].
1.2.4 Interplay between stem cells, exosomes, and microRNAs
It has been reported that exosomes secreted from stem cells have a significant role in the
paracrine signaling of transplanted stem cells [130]. Injection of exosomes derived from
CPCs into insulted mouse heart have shown regenerative effects similar to CPC transplan-
tation [131]. MSC exosomes have shown protective effects in mouse kidney injury model
by inhibiting apoptosis and increasing cell proliferation [132]. A variety of tissue regen-
eration effects of stem cell derived exosomes have been explored, such as, wound healing,
[133], skeletal muscle regeneration, [134], limb ischemia repair [135], etc. MSC derived
exosomes have been shown to alleviate liver fibrosis, increase hepatic regeneration in drug-
induced liver injury models and suppress the growth of hepatocellular carcinoma in a rat
model [136, 137, 138].
miRNA are essential for stem cell renewal, maintenance, function and are important
regulators of post-transcriptional gene expression [139]. miRNAs have been shown to reg-
ulate senescence of neural stem cells, MSCs, and HSC, by targeting genes responsible for
their epigenetic changes, metabolism and DNA damage [140, 141, 142]. Certain families
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of miRNAs play major roles in ESC cycle regulation by influencing the transition from G1
to S phase [143]. miRNAs have been shown to regulate self-renewal and proliferation of
gastric cancer stem cells as well [144]. miR-205 is highly expressed in skin stem cells and
has an important role in their neonatal expansion. Highly compromised epidermal and hair
follicle growth accompanied by neonatal lethality is caused by genetic deletion of miR-205
[145].
Exosomes are used for communication by many cell types in the body. Certain miRNAs
are secreted by Interleukin-4 (IL-4)-activated macrophages to promote the invading po-
tential of breast cancer cells [146]. A miRNA composition analysis of serum exosomes
from prostate cancer patients and healthy individuals revealed differential expression of 12
miRNAs in prostate cancer [147]. Exosome mediated transport of miR-375 from pancreas
has been shown to regulate insulin secretion [148]. Exosomes secreted by vascular en-
dothelial cells contain miR-214 which is capable of resisting vascular aging and promoting
angiopoiesis [149]. Exosomes secreted by cardiomyocytes contains miRNAs which can
reduce myocardial fibrosis and increase myocardial regeneration [150]. A few miRNAs
in exosomes released by endothelial cells play significant roles in angiogenesis and anti-
atherosclerosis [151, 149].
As shown in Figure 1.5, stem cells use exosomes for communicating with other cells,
and miRNAs are transported inside these exosomes along with other proteins, nucleic acids,
lipids, etc. In exosomes secreted from MSCs, more than 800 unique gene products and
151 distinct miRNAs have been found [152, 153]. Exosomes isolated from CPCs con-
tain several cardio-protective and pro-angiogenic miRNAs [154]. MSC derived exosomes
containing miR-21 have been shown to significantly improve cardiac function after acute
myocardial infarction by reducing apoptosis, increasing neovascularization and inducing
expression of vascular endothelial growth factor in heart [155]. CPC derived exosomes
isolated from neonates enhanced angiogenesis, decreased fibrosis, improved hypertrophy,
thereby ameliorating cardiac function in rats after ischemia– reperfusion injury. A compu-
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Figure 1.5: Schematic of exosomes aiding cell-cell communication between stem cell
and recipient cell
Along with lipids, proteins, and nucleic acids, miRNAs are packaged inside exosomes and
transported from stem cell to recipient cell for gene expression regulation in the recipient
cell. Image created using BioRender.com.
tational model was built to relate miRNA levels in exosomes with cardiac outcomes like
angiogenesis, fibrosis, ejection fraction [156].
1.3 Exosome therapy
Exosomes have drawn attention as valuable biomarkers in many pathophysiological states,
as indicators of disease progression and provide disease stage-specific information [157,
158, 159, 160]. Differences in composition of isolated exosomes and their size reflects the
type and state of the source cell. They can be secreted naturally, under cellular stress or by
activation signals and have the potential to modulate processes in which they are involved
[161]. Since these exosomes aid in cell-cell communication between distant or local cells
by transferring metabolites, nucleic acids, and lipids, they also possess the potential to im-
pact treatment of diseases [162, 163]. Exosomes can be personalized targeted drug delivery
vehicles of the future [164].
The double layered membrane and nano size of exosomes protect exosome cargoes
from damage or fast clearance by the complement fixation or macrophages, prolonging
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their half-life in circulation and enhancing their biological activity. Being natural carriers
with unique structural, compositional and morphological characteristics and fascinating
biochemical and physicochemical properties, exosomes have many other beneficial fea-
tures for therapeutic delivery like low immunogenicity, biocompatibility, biological barrier
permeability and low toxicity [165]. Exosomes released directly by budding from plasma
membrane contain surface-bound proteins of the cell from which they originated. So exo-
somes from tumor cells, antigen presenting cells, and dendritic cells are a promising source
for vaccine development. The innate therapeutic capabilities of exosomes can be further
enhanced by chemical or biological modification of their lipid bilayers, i.e., exosome engi-
neering. Hence, treatment of diseases can be facilitated by exosome mediated drug transfer
[166].
The ability to produce custom designed exosomes and modify their migratory itinerary
is incredibly important for the development of exosome therapy [167]. Parent cells can be
engineered to secrete modified exosomes by using viral and non-viral methods or contents
of secreted exosomes can be directly manipulated. Taking advantage of exosomes’ porous
structure, electroporation can be used to modify secreted exosomes, however, this method
has poor efficiency in DNA transfer [168, 169]. Basic incubation can also be used to
modify exosomes parental cells or secreted exosomes can be incubated with a drug [168].
Other techniques include lipofection, sonication, genetic engineering using viral vectors
and direct transfection [170, 167].
Currently, exosomes are being researched for aiding in drug delivery, nucleic acid de-
livery, protein delivery and immunotherapy. Scientists have engineered exosomes with re-
quired proteins and metabolites for drug delivery in cancer therapy [171]. For treatment of
Parkinson’s disease, biopharmaceutical-encoding mRNAs were inserted inside exosomes
which attenuated neuroinflammation of patients when delivered to recipient cells [172].
A genetically engineered exosome based nanosystem with immunostimulatory DNA and
endogenous tumor antigens has been shown to enhance cancer immunotherapy [173]. Hu-
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man umbilical vein endothelial cell derived exosomes, when treated with chemotherapeutic
agents, induced antitumor effects during breast cancer chemotherapy [174]. miR-314 was
highly downregulated in breast cancer tissues in comparison to healthy tissue. Exosomes
loaded miR-134 were able to reduce migration and invasion of breast cancer cells and in-
creased their sensitivity to cancer drugs [175].
Although exosome-based therapies are showing promising therapeutic effects, the are
a recent emergence and many detailed and thorough investigations are warranted to move
this therapy to clinic. For example, more research is required to find the best combinations
of exosome producing cells and target cells. A defined and uniform methodology for exo-
some isolation and characterization is required for validating numerous findings reported on
therapeutic effects of exosomes [176]. Another challenge is loading exosomes efficiently,
but without changing the structure and content of their lipid bilayer membrane [177]. On
the bright side, exosome therapy has the potential to offer unparalleled efficiency in treat-
ment of life-threatening diseases like cancer, cardiovascular diseases, including others with
lacking effective pharmacotherapy.
1.4 Partial Least Squares Regression
Partial Least Squares Regression (PLSR) is a multivariate regression method that is used
for correlating the information in one data matrix (X) to the information in another data
matrix (Y). PLSR can be used to predict or explain the behavior of hard-to-measure re-
sponse variables (Y) using controllable or easy-to-measure variables (X) [178]. With too
many independent variables (X), a multiple regression model would over-fit the sample
data, but will not be able to predict new data. In such scenarios, although there are many
independent variables (X), only a few latent variables are able to explain the most varia-
tion in response variables (Y). Basically, PLSR extracts these latent variables and explains/
predicts the responses without over-fitting. PLSR finds the latent variables that explain the
most variation in independent variables (X), the latent variables that explain the most vari-
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ation in responses (Y), and the fundamental relations between independent variables (X)
and responses (Y) [179].
Principal components, like latent variables mentioned before, are constructed as a com-
bination of initial variables that capture the most important information in the data. Load-
ings vector is a row vector that contains the combination of initial variables that define
the principal component. Scores vector is a column vector that contains the projection of
observations in the original dataset, on the principal component. The following equations
show the general model of PLSR:
X = TP T + E
Y = URT + F
where X is a n × m matrix of independent variables, Y is a n × p matrix of responses, l
being the number of principal components, T and U are n × l scores matrices of X and Y,
respectively, P and R are m × l and p × l loadings matrices of X and Y, respectively, and
E and F are error terms [178]. PLSR decomposes the X and Y matrices into its scores and
loading vectors such that the scores of X and Y have the maximum covariance. This way,
the scores of Y can be predicted using the scores of X, and subsequently Y values can be
predicted [180]. This process has been schematically explained in Figure 1.6.
There are several advantages of using PLSR. It is easy to fit PLSR models and deter-
mine their statistical properties as they are fairly simple models. PLSR generates visual
results that makes it easy to interpret the results. Loadings plot shows the influence of vari-
ables on principal components and also relationships between the variables. Scores plot
visualizes the observations with respect to principal components, thereby helping in iden-
tifying clusters or outliers in observations. PLSR is especially useful when the number of
observations is lesser than the number of variables (Linear regression fails in such cases)
[181].
PLSR modeling was used to explore relations between air pollutant levels, cytokines,
immune cell types, and blood pressure in adolescents and found that markers of acute in-
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Figure 1.6: PLSR strategy
Matrices of independent variables and responses are decomposed into scores and loadings
vectors in a way that the scores of X and Y have the maximum covariance.
flammation, oxidative stress, and monocytes, explained the most variation in air pollution
[182]. CPC RNA sequencing results analyzed with PLSR were used to make a predictive
model for cellular behaviors like migration and proliferation [183]. PLSR recognized novel
mRNA targets of miRNAs when analyzing miRNA and mRNA microarray expression pro-
files from human colon tumor tissues and normal tissues. [184] miRNA array analysis of
CPCs exosomes using PLSR revealed their miRNA-mediated reparative potential in a rat
model of ischemia–reperfusion injury [156].
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CHAPTER 2
IDENTIFICATION OF MICRORNAS FOR DOWNREGULATING CARDIAC
FIBROSIS USING COMPUTATIONAL MODELING: A META-ANALYSIS
2.1 Introduction
Cardiovascular diseases are the leading cause of mortality in the US and more than 655,000
Americans die from cardiac diseases each year, that is, one in every four deaths [185].
Cardiac remodeling changes shape, size, and composition of the heart in response to cardiac
damage or disease. Myocardial fibrosis is an important component of cardiac remodeling
and refers to the excess deposition of extracellular matrix in the cardiac muscle. Cardiac
fibrosis can lead to a stiffer myocardium, erratic heartbeats, and eventually lead to heart
failure or death [186].
Stem cells/progenitor cells use exosomes for communicating with other cells, and miRNAs
are transported inside them. As explained in the previous chapter, exosomes are extracellu-
lar vesicles that aid cell-cell communication and carry proteins, metabolites, nucleic acids,
etc. miRNAs are small non-coding RNA molecules that can be transported by exosomes
and are uniquely capable of facilitating long-term repair by altering the targeted cells’ tran-
scriptome. Previous research has demonstrated relationships between exosomal miRNA
content and fibrosis in the heart [156].
Prior research by our group (in collaboration with the Davis lab at Emory) showed that
neonate derived CPC treatment significantly reduced fibrosis compared to saline treatment
in a rat model of juvenile heart failure [37]. Masson’s trichrome staining in hearts of rats
with myocardial infarction showed lesser fibrosis when injected with CPCs compared to
cardiosphere-derived cells and controls [187]. Exosomes isolated from hypoxia treated
CPCs alleviated cardiac fibrosis when injected in a rat myocardial infarction model [85].
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miRNA content of CPC derived exosomes was related to its antifibrotic response in vitro
and was used to predict fibrotic responses to exosome treatment in vivo [188]. miRNA
content of CPC derived exosomes varied with donor age, and thereby showed different
degrees of antifibrotic effects when injected into athymic rats [156]. Together, these studies
suggest that miRNAs play a role in determining the antifibrotic effect of exosomes, and
exosomes are instrumental to the therapeutic effect of CPCs.
As next steps, our group would like to design exosomes with custom miRNA content
can that downregulate cardiac fibrosis. To achieve this goal, we need to select miRNAs
that can downregulate fibrosis and predict fibrosis responses with the miRNA signals. To
choose miRNAs and specifically to perform predictive modeling, we would need large
amount of data relating miRNA levels with cardiac fibrosis markers. So we decided to
benefit from the existing research in this field and aggregate data from the large amount of
published literature.
There are over 900 publications that studied the relationships between miRNAs and fi-
brosis markers in the heart. In this meta-analysis, expression levels of miRNAs and quanti-
ties of fibrosis markers were extracted from these papers and analyzed. PLSR models were
built to form a consensus on relationships between miRNAs and cardiac fibrosis, iden-
tify miRNAs that can downregulate cardiac fibrosis, and to predict cardiac fibrosis with
miRNAs’ fold-changes as inputs. In future studies, the data extracted in this meta-analysis
can be used to make PLSR models to analyze relations of a set of chosen miRNAs with car-
diac fibrosis and predict the extent of cardiac fibrosis when exosomes with custom-designed
packages of miRNAs are injected into animal models. This research has the potential to
inform experimental studies of cardiac remodeling.
2.2 Methodology
Literature search and categorization of publications
The following PubMed search term was used to find publications relating expression
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levels of miRNAs with cardiac fibrosis- ‘(miRNA or microRNA) and fibrosis and (heart
or cardiac)’. The process of screening and characterizing search results is explained below
and demonstrated in Figure 2.1.
Figure 2.1: Flowchart for the process of characterizing PubMed results
This flowchart describes the process of characterizing publications into six types- Graphs,
Tables, Expression array data, No data, Review and Excluded. Master sheet has two tabs-
included and excluded, and No data sheet has three tabs- Excluded, Review and No data.
Graphs, Tables, and Expression array data are three separate sheets.
If a publication was not written in English, did not discuss miRNAs, did not investigate
cardiac fibrosis, was retracted or inaccessible, it was directly excluded from this meta-
analysis. The excluded publications were listed in the excluded tab of Master sheet and
in the excluded tab of No data sheet with their reason of exclusion. If a publication was
included, the following details were documented in the included tab of the Master sheet-
publication title, summary of the paper, miRNA name, correlation with cardiac fibrosis,
measure of fibrosis and data availability. If the included publication was a review article,
it was listed in the review tab of the No data sheet. On the other hand, if it was a research
article, it was further evaluated for inclusion in the meta-analysis. If miRNA and cardiac
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fibrosis were not quantified for same experimental conditions, this paper was listed in the
No data tab of the No data sheet with a reason for the same. If miRNA and cardiac fibrosis
were quantified for same experimental conditions, depending on the available data type,
publications were put into these three categories- Graphs, Tables, Expression array data. If
multiple types of data is available in the paper, it was put into a category using the following
priority order: Expression array data > Tables > Graphs. This priority order was used as
maximum data should be extracted from publications for the meta-analysis. The process of
categorizing publications into these sheets has been schematically explained in Figure 2.1.
Reasons of allotting publications into specific categories have also been summarized in
Table 2.1.
Table 2.1: Reasons for categorizing PubMed search results into specific categories
Reasons for categorizing PubMed search results into specific sheets and tabs are summa-
rized.
Sheet name Tab name Reason
Master sheet Included The publication is written in English, discusses miRNAs
and cardiac fibrosis, is not retracted and is accessible.
Master sheet Excluded The publication is not written in English, does not discuss
miRNAs or cardiac fibrosis, is retracted or inaccessible.
No data No data The publication is included but has not quantified miRNA,
cardiac fibrosis, or both of them have not been quantified
for same experimental conditions.
No data Review The publication is included but it is a review article
No data Excluded Same as in the excluded tab of Master sheet
Graphs The publication is included, is a research article and has
quantified both miRNA and fibrosis for same experimental
conditions in a graphical format.
Tables The publication is included, is a research article and has
quantified both miRNA and fibrosis for same experimental
conditions. At least one of them has been presented in a
tabular format.
Expression The publication is included, is a research article and has
array data quantified both miRNA and fibrosis for same experimental
conditions. Entire expression array data is available at
least for miRNAs.
Data Extraction and consolidation- Fold change and p-value
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For extracting data from graphs, snippets of graphs were uploaded into graphreader.com,
axis were adjusted and labeled, and values were noted by hovering the cursor over the
graph. Data from graphs was extracted into excel sheets with rows being the variables
(miRNAs, mRNAs, proteins, etc.) and columns being the experiments (observations).
Then fold changes were calculated for the experiments that had significantly different (p-
value<0.05) values for both miRNAs and fibrosis markers. P-values were also noted paral-
lelly with fold changes. Fold changes and p-values were readily available for data in tabular
format. Therefore, when extracting data from tables, for each experiment, fold changes and
p-values of variables were directly copied and pasted into excel sheets for both miRNAs
and fibrosis markers. When the entire expression array data was available for an experi-
ment, it was first copied into an excel sheet. Fold changes and p-values were calculated in
excel for both miRNAs and fibrosis markers. Fold change was calculated by taking ratio
of mean expression values for any two conditions. P-values for the same conditions were
calculated using two-tailed Student’s t-test where expression values of the two conditions
were input as array one and array two, respectively.
Fold changes from all the graphs were compiled into one sheet with rows being the ex-
periments from publications (observations) and columns being miRNAs and fibrosis mark-
ers (variables). The same process was followed for data in tables, and in expression array
format as shown in Figure 2.2a. These three sheets were then consolidated into one single
sheet and converted to log-base 2 scale. Similarly, p-values from excel sheets of graphs,
tables, and expression array were compiled into one sheet as shown in Figure 2.2b. Further
analysis for establishing relationships between miRNAs and fibrosis markers used the two
files with consolidated fold changes and p-values data from all selected publications.
All miRNAs found were included in the analysis but only the following fibrosis markers
were considered: Masson trichrome staining, Picrosirius red staining, Collagen type I alpha
1 chain (COL1A1) mRNA, Collagen type I alpha 2 chain (COL1A2) mRNA, Collagen type
III alpha 1 chain (COL3A1) mRNA, CTGF mRNA, Vimentin (VIM) mRNA, Collagen 1
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(a) Extraction and consolidation process of fold change data
(b) Extraction and consolidation process of p-value data
Figure 2.2: Extraction and consolidation process of fold change and p-value data from
publications selected for meta-analysis
Extraction and consolidation process of fold change and p-value data of miRNAs and fi-
brosis markers- starting from data in form of graphs, tables, expression array data in pub-
lications selected for meta-analysis, to one final sheet for fold change and p-value data,
respectively.
protein, Collagen 3 protein, CTGF protein and Vimentin protein. The fibrosis markers
were selected based on prior research and were also in sync with the previous experiments
conducted as a part of the collaboration (with Davis lab at Emory) this project is a part of.
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A list of miRNAs with their number of experiments was made using the consolidated
fold change file. Similarly, a list was compiled for fibrosis markers with their number of
experiments. To find the number of publications that studied each miRNA, the following
data was documented and grouped together- miRNA name, correlation with cardiac fibrosis
and source publication title. miRNAs with same precursor miRNA were placed with each
other, for example, miR-29, miR-29a-3p, and miR-29b were grouped together.
Scoring formulae weighting for fold change, p-value and miRNAs’ number of experi-
ments were developed to select highly correlated miRNAs with cardiac fibrosis
Three scoring models were used to rank ∼5000 miRNAs based on the magnitude and
consistency of their correlation with cardiac fibrosis- each having different weights for
fold-change, p-value and miRNAs’ number of experiments. Model 1 scoring formulae
were unbiased towards miRNAs’ number of experiments, model 2 scoring formulae were
biased towards well-studied miRNAs and model 3 scoring formulae were biased towards






































































































numExpts→ number of experiments the miRNA was analysed in and
maxNumExpts→ maximum number of experiments any miRNA was analysed in.
Each scoring formula calculates one number for each miRNA, based on miRNA’s fold
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changes and p-values, fold changes and p-values of corresponding fibrosis markers, and the
number of experiments that miRNA has been studied in. This correlation number is then
used to rank the miRNAs for that formula.
miRNAs having positive correlation with cardiac fibrosis had a positive score and
miRNAs having negative correlation with cardiac fibrosis had a negative score. For both
positively and negatively correlated miRNAs, top 200 miRNAs having the highest absolute
value of correlation were noted for each scoring formula. For each scoring model, two
Venn diagrams were made to show the number of miRNAs which were common among
the top 200 of each formula, separately for positively and negatively correlated miRNAs.
The miRNAs that were common among top 200 miRNAs of all scores, for either positive
or negative correlation, were noted separately. Fold change data for these miRNAs was
extracted from the previously consolidated fold change data sheet and was used for further
analysis.
Partial Least Squared Regression (PLSR) modeling and optimization based on model
fitting and prediction accuracy values
PLSR modeling was used to quantify the relationships between fold changes of miRNAs
and fibrosis markers in the heart. In PLSR models, miRNAs were as x-variables, fibrosis
markers were y-variables, and experiments were observations. SIMCA-P software (Umet-
rics, Sartorius Stedim Biotech, Ume°a, Sweden) was used to build PLSR models for a
variety of conditions and to calculate their model fitting and prediction accuracy values.
For each scoring model, a PLSR was built from the miRNAs selected by that model and
fibrosis markers. To increase the model fitting and prediction accuracy of this PLSR model,
a couple of selection criterion were applied on miRNAs and fibrosis markers. Fibrosis
markers that had the maximum absolute value of PLSR coefficient with miRNAs greater
than 0.1 were selected. For each chosen fibrosis marker, miRNAs were ranked based on
their absolute value of PLSR coefficient. miRNAs belonging to the intersection of top 10%
miRNAs for each selected fibrosis marker were selected. A PLSR model was trained on
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these selected miRNAs and fibrosis markers.
Variable importance in projection (VIP) score is a measure of a variable’s importance
in a PLSR model and demonstrates its contribution to the model. To further optimize the
PLSR model, miRNAs having a VIP score greater than 1 and lower limit of VIP standard
error above 0 were selected. These miRNAs were used to calculate model fitting and pre-
diction accuracy value for each fibrosis marker. The model fitting and prediction accuracy
values for each fibrosis marker was documented in a table. Fibrosis markers with the best
model fitting and prediction accuracy values were selected. The PLSR model made with
the VIP miRNAs and selected fibrosis markers had the maximum model fitting and pre-
diction accuracy values. A loadings plot was made for this PLSR model to visualize the
relationships between the selected miRNAs and fibrosis markers.
Literature validation of meta-analysis results using publications selected for qualita-
tive analysis and miRTarBase.
For the miRNAs that were identified to downregulate cardiac fibrosis, following values
were calculated based on the data aggregated from literature for qualitative analysis- num-
ber of research and review articles that reported a relationship between the miRNA and
cardiac fibrosis, number of publications in which the miRNA caused or inhibited cardiac
fibrosis, number of experiments in which the expression of miRNA varied by more than
two folds in cardiac fibrosis versus control condition, and number of papers which were
published from the collaborative project with Davis lab and identified the miRNA to be cor-
related with cardiac fibrosis. To go in further detail on how the miRNA caused/inhibited
cardiac fibrosis, the number of publications in which the miRNA was forcefully overex-
pression/ underexpressed were documented. For the same miRNAs, scoring models that
identified that they could downregulate cardiac fibrosis and their effect on cardiac fibro-
sis as concluded from the meta-analysis were also noted. This entire aggregated data was
condensed into a form of a table.
While making the optimized PLSR for miRNAs from scoring model 3 (biased to-
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wards under-studied miRNAs), many miRNAs that were in first set of chosen miRNAs
(selected using miRNA-fibrosis marker PLSR coefficients) were not present in the opti-
mized model. To explore if these miRNAs had cardiac fibrosis related target genes, the
miRNAs were queried in miRTarBase [189] for homo sapiens, mus musculus, and rattus
norvegicus species. For each miRNA, the following cardiac fibrosis markers were searched
in its target genes: COL1A1 mRNA, COL1A2 mRNA, COL3A1 mRNA, CTGF mRNA,
and VIM mRNA. A table was made with these miRNAs and their cardiac fibrosis related
target genes.
PLSR models were used to predict fibrosis markers in in silico experiments with
downregulated profibrotic miRNAs and upregulated antifibrotic miRNAs
The optimized PLSRs from each scoring model were used to predict the levels of the
following fibrosis markers: Masson trichome stained area, COL1A1 mRNA, and Collagen
1 protein. Profibrotic miRNAs were downregulated and antifibrotic miRNAs were upreg-
ulated for 30 in silico experiments. miRNA data was randomly generated using RAND()
function in excel for three models. For upregulation, log2(fold-change) value was between
0 and 5 and for downregulation, log2(fold-change) value was between -5 and 0. Fibrosis
markers were predicted for the three PLSR models and the results were compared using
two-tailed Student’s t-test.
2.3 Result
Searched PubMed, screened search results, and selected 248 articles for meta-analysis
PubMed was searched for publications relating expression levels of miRNAs with car-
diac fibrosis and 911 search results were obtained. These publications were screened using
multiple criterions as shown in Figure 2.3. 189 articles were excluded in the first step due
to one of the following reasons- not written in English, did not discuss miRNAs, did not
investigate cardiac fibrosis, was retracted or inaccessible. Remaining 511 research articles
and 211 review articles were included in the qualitative study. For the meta-analysis, data
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was extracted from 248 research articles that quantified miRNA and cardiac fibrosis for
same experimental conditions.
Figure 2.3: Flow diagram describes the process of screening PubMed search results
and selecting 248 articles for meta-analysis
911 PubMed results were obtained using the search term- “(miRNA or microRNA) and
(heart or cardiac) and fibrosis”. These publications were screened, and finally 248 papers
were selected for computational modeling. The flow diagram shows 911 initial PubMed
results, 722 publications included for qualitative analysis, 511 research articles and 248
publications selected for meta-analysis analysis- with data in graphical, tabular and expres-
sion array data format.
List of the most frequently analyzed miRNAs with their number of experiments in pub-
lications selected for meta-analysis is shown in Table 2.2. The relationships of miR-21,
miR-29 family, miR-133a with cardiac fibrosis have been analyzed in the maximum num-
ber of experiments. A list of the most frequently analyzed fibrosis markers with their num-
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ber of experiments in publications selected for meta-analysis is shown in Table 2.3. Col-
lagen mRNAs, proteins and Masson Trichrome staining have been mostly used to quantify
cardiac fibrosis in experiments.
Table 2.2: List of the most frequently analyzed miRNAs with their number of experi-
ments in publications selected for meta-analysis
miRNA name Number of miRNA name Number of miRNA name Number of
experiments experiments experiments
miR-21 102 miR-378 28 miR-29b-3p 22
miR-29b 85 miR-15b 27 miR-423-3p 22
miR-29a 67 miR-142-3p 26 miR-27a 22
miR-29c 62 miR-10a 26 miR-331-3p 21
miR-133a 55 miR-25 26 miR-328 21
miR-132 39 miR-30a 26 miR-455 21
miR-1 36 miR-125b 26 miR-199a-3p 20
miR-26b 36 miR-145 26 miR-29c-3p 20
miR-26a 33 miR-214 26 miR-339-5p 20
miR-30c 32 miR-19b 25 miR-345-5p 20
miR-34a 30 miR-199a-5p 24 let-7c 20
miR-133b 29 miR-221 24 miR-22 20
miR-155 29 miR-143-3p 23 miR-27b 20
miR-223 29 miR-130a 23 miR-140-3p 19
miR-155-5p 28 miR-125a-5p 22 miR-151-5p 19
Table 2.3: List of the most frequently analyzed fibrosis markers with their number of
experiments in publications selected for meta-analysis
Fibrosis marker name Number of experiments
COL1A1 mRNA 363
Collagen 1 protein 246
COL3A1 mRNA 242
Masson Trichrome 229








Scoring models selected miRNAs that were highly correlated with cardiac fibrosis
Data for over 5000 miRNAs was extracted from the publications selected for meta-
analysis. Model 1 had two scoring formulae and was unbiased towards miRNAs’ number
of experiments. Models 2 and 3 had 4 scoring formulae each and were biased towards
well-studied and under-studied miRNAs, respectively. Every scoring model was used to
rank∼5000 miRNAs based on the magnitude and consistency of their correlation with car-
diac fibrosis- each formula having different weights for fold-change, p-value and miRNAs’
number of experiments.
Venn diagrams in Figure 2.4a, Figure 2.4b show that 184 highly positively correlated
miRNAs were selected, and 123 highly negatively correlated miRNAs were selected for
PLSR modeling with scoring model that was unbiased towards miRNAs’ number of exper-
iments. 170 (positive) and 121 (negative) miRNAs were selected using the scoring model
biased towards well-studied miRNAs (Figure 2.5a, Figure 2.5b). Similarly, 186 highly
positively correlated and 120 highly negatively correlated miRNAs were selected with the
scoring model that was biased towards under-studied miRNAs (Figure 2.6a, Figure 2.6b).
Fold change data of these selected miRNAs was extracted from previously consolidated
fold change data sheet and was used for PLSR analysis.
PLSR modeling identified miRNAs that can downregulate cardiac fibrosis
Relationships between expression levels of miRNAs and quantities of fibrosis markers
in the heart were quantified with PLSR modeling for the three scoring models. Model
fitting and prediction accuracy values were used to measure the optimization of the model.
For scoring model 1, PLSR model made with 307 miRNAs selected using scoring for-
mulae and 11 fibrosis markers had model fitting value of 0.44 and prediction accuracy
value of 0.30. To improve the model fitting and prediction accuracy of this model, 8 fibro-
sis markers having the maximum absolute value of PLSR coefficient with miRNAs greater
than 0.1 in this PLSR model were selected. Subsequently, miRNAs were ranked based
33
Figure 2.4: PLSR modeling identified six miRNAs that can downregulate cardiac fi-
brosis using scoring formulae unbiased towards miRNAs’ number of experiments
Model 1 had two scoring formulae that were used to rank ∼5000 miRNAs based on the
magnitude and consistency of their correlation with cardiac fibrosis- each having different
weights for fold-change, p-value and were unbiased towards miRNAs’ number of exper-
iments. A) 200 miRNAs with the highest positive correlation were selected from each
scoring formula, and the overlap in the Venn Diagram shows 184 common miRNAs that
were used in further analysis. B) Similarly, 123 miRNAs were selected as highly neg-
atively correlated miRNAs. C) Together for 307 miRNAs and fibrosis markers, PLSR
models were trained using experimental data extracted from publications selected for meta-
analysis. Based on miRNA-fibrosis marker PLSR coefficients and VIP scores, PLSR mod-
eling found 6 miRNAs (miR-33, miR-26a, miR-30c, miR-125b, miR-155-5p, miR-34a)
that can explain and predict cardiac fibrosis (COL1A1 mRNA, Collagen 1 protein). R2Y→
model fitting value and Q2 → prediction accuracy value.
on their absolute value of PLSR coefficient for each chosen fibrosis marker. 19 miRNAs
in the intersection of top 10% miRNAs for each selected fibrosis marker were selected.
The PLSR model trained on these selected miRNAs and fibrosis markers had improved
model fitting (0.48) and prediction accuracy (0.39) values. To optimize this model further,
6 miRNAs with VIP score greater than 1 and lower limit of VIP standard error above 0
were selected from this model. Then, a PLSR model was made for each fibrosis marker
from the selected miRNAs. PLSR model fitting and prediction accuracy values for each fi-
brosis marker have been shown in Table 2.4. COL1A1 mRNA and Collagen 1 protein were
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Figure 2.5: PLSR modeling identified five miRNAs that can downregulate cardiac fi-
brosis using scoring formulae biased towards well-studied miRNAs
Model 2 had four scoring formulae that were used to rank ∼5000 miRNAs based on the
magnitude and consistency of their correlation with cardiac fibrosis- each having different
weights for fold-change, p-value and were biased towards miRNAs’ number of experi-
ments. A) 200 miRNAs with the highest positive correlation were selected from each
scoring formula, and the overlap in the Venn Diagram shows 170 common miRNAs that
were used in further analysis. B) Similarly, 121 miRNAs were selected as highly neg-
atively correlated miRNAs. C) Together for 291 miRNAs and fibrosis markers, PLSR
models were trained using experimental data extracted from publications selected for meta-
analysis. Based on miRNA-fibrosis marker PLSR coefficients and VIP scores, PLSR mod-
eling found 5 miRNAs (miR-21, miR-29b, miR-29a, miR-26a, miR-33) that can explain
and predict cardiac fibrosis (CTGF mRNA, Collagen 1 protein). R2Y→ model fitting value
and Q2→ prediction accuracy value.
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Figure 2.6: PLSR modeling identified four miRNAs that can downregulate cardiac fi-
brosis using scoring formulae biased towards under-studied miRNAs
Model 3 had four scoring formulae that were used to rank ∼5000 miRNAs based on the
magnitude and consistency of their correlation with cardiac fibrosis- each having different
weights for fold-change, p-value and were biased against miRNAs’ number of experiments.
A) 200 miRNAs with the highest positive correlation were selected from each scoring for-
mula, and the overlap in the Venn Diagram shows 186 common miRNAs that were used in
further analysis. B) Similarly, 120 miRNAs were selected as highly negatively correlated
miRNAs. C) Together for 306 miRNAs and fibrosis markers, PLSR models were trained
using experimental data extracted from publications selected for meta-analysis. Based
on miRNA-fibrosis marker PLSR coefficients and VIP scores, PLSR modeling found 4
miRNAs (miR-33, miR-155-5p, miR-29a, miR-29c) that can explain and predict cardiac fi-
brosis (CTGF mRNA, Collagen 1 protein, Collagen 3 protein). R2Y→ model fitting value
and Q2→ prediction accuracy value.
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predicted significantly better than other cardiac fibrosis markers and were used in the final
model. The optimized PLSR model made with the 6 VIP miRNAs and 2 selected fibrosis
markers had the best model fitting (0.63) and prediction accuracy (0.56) values. The flow
and results of this optimization has been demonstrated in Figure 2.4c. Similarly, the PLSR
optimization results for scoring models 2 and 3 are shown in Figure 2.5c and Figure 2.6c.
Table 2.4: Model fitting and prediction accuracy values for fibrosis markers from
PLSRs made using miRNAs that can downregulate cardiac fibrosis
Model 1 scoring formulae were unbiased towards miRNAs’ number of experiments, model
2 scoring formulae were biased towards well-studied miRNAs and model 3 scoring for-
mulae were biased towards under-studied miRNAs. After the first round of selection of
miRNAs and fibrosis markers for each scoring model, miRNAs with VIP score > 1 and
lower limit of VIP standard error above 0 were chosen. These miRNAs were used to make
a PLSR model for each fibrosis marker with the experimental data extracted from publica-
tions selected for meta-analysis. Fibrosis markers with the highest PLSR model fitting and
prediction accuracy values were used in the optimized PLSR model as markers of cardiac
fibrosis and their values been marked in bold. R2Y→ model fitting and Q2→ prediction
accuracy
Fibrosis marker name Model 1 Model 2 Model 3
R2Y Q2Y R2Y Q2Y R2Y Q2Y
COL1A1 mRNA 0.57 0.53 0.43 0.38 0.43 0.37
Collagen 1 protein 0.73 0.67 0.66 0.57 0.47 0.46
COL3A1 mRNA 0.51 0.43 0.44 0.35 0.49 0.45
Masson Trichrome 0.43 0.37 0.49 0.47 0.36 0.23
Collagen 3 protein 0.59 0.41 0.45 0.18 0.66 0.68
CTGF mRNA 0.51 0.49 0.66 0.64 0.54 0.41
Picrosirius red 0.43 0.13 0.28 0.15 0.08 0.21
CTGF protein 0.53 0.49 NA NA NA NA
Loadings plot from the final PLSRs, corresponding to the three scoring models, have
been shown in the Figure 2.7. They visualize relationships between the miRNAs and fi-
brosis markers. For the loadings plot from scoring model 1, the principal component 1
explained 71% of the variability, much greater than that explained by the second princi-
pal component (18%). Hence, it is evident that miRNAs on the right side of y axis are
negatively correlated with cardiac fibrosis whereas miRNAs on the left side of y axis are
positively correlated with cardiac fibrosis. Similarly, profibrotic and antifibrotic miRNAs
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can be seen in loadings plots from scoring models 2 and 3.
In summary, the three scoring models and PLSR modeling identified miR-21, miR-33,
miR-125b, miR-155-5p, miR-34a as profibrotic miRNAs and miR-29b, miR-29a, miR-26a,
miR-30c, miR-29c as antifibrotic miRNAs.
Literature validation of meta-analysis results and miRNA analysis on miRTarBase
revealed under-studied miRNAs that can downregulate cardiac fibrosis
Meta-analysis miRNA findings were validated from literature. Publications that were
initially selected for qualitative analysis were used to find information on the miRNAs that
have been identified to downregulate cardiac fibrosis. Many values related to miRNAs’ re-
lationship with cardiac fibrosis were documented as described in the Methods section and
are shown in Table 2.5. Based on the aggregated data, it can be observed that miRNAs from
scoring model 2 have been studied more in the literature as scoring model 2 was biased to-
wards well-studied miRNAs. However, there was not much difference in the number of
publications that studied miRNAs corresponding to scoring models 1 and 3. miR-29 and
miR-34a have been shown to inhibit cardiac fibrosis by both overexpression and underex-
pression in different conditions. Most of these identified miRNAs have been observed to
affect cardiac fibrosis in the experiments performed as a part of the collaborative project
with the Davis lab.
After the first round of selection of miRNAs and fibrosis markers in scoring model 3, 24
miRNAs were selected. Out of them, only 4 miRNAs were present in the optimized PLSR
model. Table 2.6 shows the fibrosis related target genes of the remaining 20 miRNAs.
miR-29b-3p and miR-29c-3p target collagen mRNAs, 8 miRNAs target CTGF mRNA, and
6 miRNAs target VIM mRNA.
PLSR models predicted downregulation of cardiac fibrosis when profibrotic miRNAs
were downregulated and antifibrotic miRNAs were upregulated
The level of fibrosis markers was predicted using the optimized PLSR models from the
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Figure 2.7: PLSR loadings plots shows profibrotic and antifibrotic miRNAs from three
scoring models differently biased toward miRNAs’ number of experiments
After the first round of selection of miRNAs and fibrosis markers for each scoring model,
miRNAs with VIP score > 1 and lower limit of VIP standard error above 0 were chosen.
Subsequently, the fibrosis markers that were best predicted by these miRNAs were se-
lected. An optimized PLSR was made for each scoring model using the selected miRNAs
and fibrosis marker. In the three PLSR models, principal component 1 explains the most
variability. Hence, loadings plots from these PLSR models shows that miRNAs on one
side of y axis (with fibrosis markers) are positively correlated with cardiac fibrosis whereas
miRNAs on the other side of y axis are negatively correlated with cardiac fibrosis.
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Table 2.5: Literature validation of meta-analysis results revealed under-studied
miRNAs that can downregulate cardiac fibrosis
Meta-analysis miRNA findings were validated from publications selected for qualitative
analysis. Following was documented for the miRNAs that were identified to downreg-
ulate cardiac fibrosis- scoring models that identified that the miRNA can downregulate
cardiac fibrosis, effect on cardiac fibrosis as concluded from the meta-analysis, number of
publications they were studied in, number of experiments where they caused or inhibited
cardiac fibrosis, number of experiments in which the expression of miRNA varied by more
than two folds in cardiac fibrosis versus control condition, and number of papers which
were published from the collaborative project with Davis lab and identified the miRNA to
be correlated with cardiac fibrosis. Literature analysis shown in the table gives a list of
under-studied miRNAs that might be important regulators of cardiac fibrosis and should
be investigated further to consolidate their roles in cardiac fibrosis. Number of research
and review articles are separated by a ‘+’ sign. KO: Knockout, expts: experiments, FC:
fold-change, N.: Number of, M1: Scoring model 1, M2: Scoring model 2, M3: Scoring
model 3, Pro: Profibrotic, Anti: Antifibrotic, Ago: Agomir, Antago: Antagomir
N. Cardiac N. Cardiac
fibrosis fibrosis
causation inhibition
miRNA Scoring Effect N. Ago Antago Ago Antago N. expts N.
name models on papers / KO / KO with Davis
cardiac | log2FC | Platt
fibrosis > 2 papers
miR-21 M2 Pro 75+111 10 21 29 0
miR-29b M2 Anti 45+101 9 9 1 11 2
miR-29a M2, M3 Anti 37+101 5 6 2 5 1
miR-26a M1, M2 Anti 8+15 2 4 4 1
miR-33 M1, M2, Pro 2+1 2 4 2
M3
miR-30c M1 Anti 11+43 3 2 6 1
miR-125b M1 Pro 6+14 2 3 8 3
miR-155 M1, M3 Pro 17+6 4 9 1 0
-5p
miR-34a M1 Pro 11+22 2 1 6 5 1
miR-29c M3 Anti 28+93 2 3 1 12 1
three scoring models. 30 in silico experiments were conducted to downregulate cardiac
fibrosis, as described in the Methods section, and the results were compared using two-
tailed Student’s t test as shown in Figure 2.8. Masson Trichrome stained area, COL1A1
mRNA expression level and Collagen 1 protein level were predicted to be downregulated in
all models. Log2(fold-change) values of fibrosis markers, as predicted by the three PLSR
models, were significantly different from each other.
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Table 2.6: Selected under-studied miRNAs have cardiac fibrosis-related target genes
After the first round of selection of miRNAs and fibrosis markers in scoring model 3, 24
miRNAs were selected. Out of them, only 4 miRNAs were present in the optimized PLSR
model. This table shows the fibrosis related target genes of the remaining 20 miRNAs.
These miRNAs were queried in miRTarBase [189] for homo sapiens, mus musculus, and
rattus norvegicus species. For each miRNA, the following cardiac fibrosis markers were
searched in its target genes : COL1A1 mRNA, COL1A2 mRNA, COL3A1 mRNA, CTGF
mRNA, and VIM mRNA. The miRNAs in this table with listed target genes might have
important roles in cardiac fibrosis. However, they were not selected as regulators of cardiac
fibrosis in this meta-analysis, mostly because they did not have enough data in selected
publications. Hence, these miRNAs should be investigated further to explore their roles in
cardiac fibrosis.
miRNA name Target genes miRNA name Target genes
miR-26b CTGF, COL1A2, VIM miR-122 CTGF
miR-143-3p COL1A1, COL3A1, CTGF miR-214-3p CTGF
miR-125b None miR-133 CTGF, COL1A1
miR-145 CTGF miR-223 VIM
miR-34a None miR-30c-5p CTGF, VIM
miR-29b-3p COL1A1, COL1A2, COL3A1 miR-208b-3p None
miR-30a VIM miR-30c-1-3p None
miR-30c CTGF, VIM miR-181d None
miR-455 COL3A1 miR-29c-3p COL1A1, COL1A2, COL3A1
miR-378 VIM miR-433 None
Build a PLSR model to analyze relationships between a set of chosen miRNAs and
cardiac fibrosis using meta-analysis data
Following steps should be followed to build a customized PLSR model:
1. Choose a set of miRNAs
2. From the log2(fold-change) datasheet, select columns of chosen miRNAs and all
fibrosis markers
3. Remove the remaining columns of miRNAs and the experiments that do not contain
any data of chosen miRNAs
4. The PLSR model will be built on this tailored dataset to find relationships between
the chosen set of miRNAs and cardiac fibrosis- assign miRNAs as x variables, fibro-
sis markers as y-variables, and experiments as observations
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Figure 2.8: PLSR models predicted downregulation of cardiac fibrosis when profi-
brotic miRNAs were downregulated and antifibrotic miRNAs were upregulated
A) Data was randomly generated for miRNAs that were identified to downregulate cardiac
fibrosis in the three scoring models. Downregulated profibrotic and upregulated antifibrotic
miRNAs’ inputs, constrained within the log2FC limits mentioned in the figure (number of
experiments = 30), were used to predict the following three fibrosis markers: B) Masson
Trichrome stained area, C) COL1A1 mRNA expression level and D) Collagen 1 protein
level were predicted to be downregulated by all models. log2FC values of fibrosis mark-
ers, as predicted by the three PLSR models, were significantly different from each other.
All data are represented as mean ± SD. ***P < 0.001, **P < 0.01, *P < 0.05. Data were
analyzed using two-tailed Student’s t-Test. FC: fold-change.
This process has been demonstrated in Figure 2.9. This workflow can be used to analyze
relationships between a set of chosen miRNAs and cardiac fibrosis, and eventually to pre-
dict cardiac fibrosis using the trained PLSR model, given the input fold-change data for the
set of chosen miRNAs.
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Figure 2.9: Build a PLSR model to analyze relationships between a set of chosen
miRNAs and cardiac fibrosis using meta-analysis data
Choose a set of miRNAs. From the log2(fold-change) datasheet, select columns of cho-
sen miRNAs and all fibrosis markers. Remove the remaining columns of miRNAs and the
experiments that do not contain any data of chosen miRNAs. The PLSR model will be
built on this tailored dataset to find relationships between the chosen set of miRNAs and
cardiac fibrosis. For PLSR modeling, assign miRNAs as x variables, fibrosis markers as
y-variables, and experiments as observations. Expt: Experiment, FM: fibrosis marker.
2.4 Discussion
This chapter demonstrated the methods and results of a meta-analysis relating expression
levels of miRNAs with quantities of fibrosis markers in the heart using data extracted from
43
published research articles. PubMed generated 911 search results when searched for publi-
cations relating expression levels of miRNAs with cardiac fibrosis and approximately 80%
of these results were included in the qualitative analysis. Only 27% of the search results
were used in the meta-analysis because many research papers did not quantify miRNA and
fibrosis markers for the same experimental conditions. Most of the publications selected
for meta-analysis had data in graphical format. Very few papers published their expression
array data.
Three scoring models were made to find miRNAs that were highly correlated with car-
diac fibrosis- model 1 was unbiased towards miRNAs’ number of experiments, model 2
was biased towards well-studied miRNAs and model 3 was biased towards under-studied
miRNAs. In models, each scoring formula weighted fold change, p-value and miRNAs’
number of experiments differently. For example, in model 2, formulae 2 and 4 has square
root of numExpts, hence decreasing its importance in determining the correlation value.
In model 3, formulae 3 and 4 multiples p-values in the denominator, thereby giving more
weight to p-values in comparison to formulae 1 and 2. So a combination of these scoring
formulae covers multiple aspects of analyzing the consistency and magnitude of corre-
lation between miRNAs and cardiac fibrosis for each scoring model. Correlation scores
were calculated for ∼5000 miRNAs and only top 200 positively and negatively correlated
miRNAs were selected from each formula. For the three scoring models, positively corre-
lated miRNAs had a greater overlap among the top 200 miRNAs from constituent formulae,
in comparison to negatively correlated miRNAs. The formulae that have a lesser overlap
of top 200 negatively correlated miRNAs have different weights of p-values, as evident
from the Venn diagrams of scoring models. Hence, we can infer that p-values had greater
influence in determining the correlation coefficient for negatively correlated miRNAs than
positively correlated miRNAs with cardiac fibrosis.
PLSR modeling was used to quantify the relationships between miRNAs and fibrosis
markers in the heart. For each scoring model, miRNAs and fibrosis markers were se-
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lected using multiple criteria to make the most optimized PLSR model with the maximum
model fitting and prediction accuracy value. The optimized PLSR model obtained from the
miRNAs from scoring model 2 had the best model fitting and prediction accuracy value,
followed by model 1 and model 3. This is because model 2 was biased towards well-
studied miRNAs that had more experimental data to train the PLSR model than the under-
studied miRNAs of model 3 as shown in Table 2.2. It is also possible that the miRNAs
that have been studied more with respect to cardiac fibrosis, actually target cardiac fibrosis
related genes well. The fibrosis markers selected in the optimized PLSR models (based
on selection criteria) for the three scores were the frequently analyzed fibrosis markers in
experiments from publications selected for meta-analysis as shown in Table 2.3.
Publications that were initially selected for qualitative analysis were used to validate
meta-analysis findings. Publications validated the meta-analysis results: overexpression
of profibrotic miRNAs from the meta-analysis (like miR-21) have been shown to increase
cardiac fibrosis [190] and their underexpression have been shown to inhibit cardiac fibrosis
[191]. Similar observations were made for antifibrotic miRNAs like miR-26a [192, 193].
Literature analysis revealed that some miRNAs, for example miR-33, that might be im-
portant regulators of cardiac fibrosis and should be investigated further to consolidate their
roles in cardiac fibrosis. The analysis of under-studied miRNAs using miRTarBase [189]
indicated that the miRNAs with cardiac fibrosis related target genes might have important
roles in cardiac fibrosis like miR-122. However, they were not selected as regulators of
cardiac fibrosis in this meta-analysis, mostly because they did not have enough data in se-
lected publications. Hence, these miRNAs should be investigated further to explore their
roles in cardiac fibrosis.
For each scoring model, its optimized PLSR was used to predict the log2(fold-change)
of Masson Trichrome stained area, COL1A1 mRNA and Collagen 1 protein when profi-
brotic miRNAs were downregulated and antifibrotic miRNAs were upregulated. Model
3 that was biased towards the under-studied miRNAs showed the least downregulation of
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cardiac fibrosis markers. Lack of experimental data for the under-studied miRNAs might
be the reason behind this prediction. It is also possible that under-studied miRNAs do not
target cardiac fibrosis that well.
Five profibrotic and five antifibrotic have been reported in this meta-analysis. All an-
tifibrotic miRNAs target collagen genes and profibrotic miR-34a, miR-155-5p, miR-125b
target genes of ECM-degrating MMP enzymes [194]. miR-21 has shown to cause fibro-
sis after myocardial infarction via TGF-β/Smad7 signaling pathway [195]. miR-29b de-
creased myocardial fibrosis in a mouse model of hypertension by targeting TGF-β/Smad7
pathway [196]. Its has been reported that miR-33 promotes cardiac fibrosis by stimulating
p38 MAPK signaling and inhibiting MMP16 [197]. Antifibrotic miR-26a targets collagen
1 and CTGF, and inhibits inflammatory cytokine producing NF-κB [198]. miR-125b has
been shown to cause fibrosis by inhibiting p53 to induce fibroblast proliferation, and causes
fibroblast-to-myofibroblast transition [199]. miR-155-5p has been shown to promote car-
diac fibrosis by targeting TGF-β-inhibiting c-Ski [200]. miR-34a has been reported to
cause cardiac fibrosis post myocardial infarction by targeting Smad4, involved in TGF-β
signaling [201].
Tissue remodeling and fibrotic scaring can occur in other organs like lung, kidney and
liver post injury. Along with cardiac fibrosis, upregulated miR-21 has been reported to
be involved in pulmonary fibrosis, renal fibrosis and kidney fibrosis [202, 203, 204]. On
the other hand, downregulated miR-29 family has been shown to cause renal fibrosis, pul-
monary fibrosis, and hepatic fibrosis [205, 206, 207]. miR-26a has been shown to decrease
pulmonary fibrosis and lens fibrosis [208, 209]. Inhibition of miR-33 downregulates renal
fibrosis [210]. miR-30c is involved in decreasing hepatic and renal fibrosis [211, 212].
miR-125 promotes hepatic fibrosis [213]. miR-155-5p is involved in renal and pulmonary
fibrosis. Upregulation of miR-155-5p inhibits pulmonary fibrosis but causes renal fibrosis
[214, 215] miR-34a promotes pulmonary, hepatic and renal fibrosis [216, 217, 218]. It can
be observed that mostly the relations between miRNA and cardiac fibrosis concluded from
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this meta-analysis are true for fibrosis in other organs as well. However, miRNAs need to
be carefully chosen for decreasing cardiac fibrosis as sometimes they can increase fibrosis
in other organs. This indicates that after computational selection of miRNAs, another level
of literature verification is needed to ensure that changing expression levels of a miRNA
for decreasing cardiac fibrosis does not lead to another disease.
To the best of our knowledge, this meta-analysis is the first of its kind. No meta-
analysis has been performed to consolidate relationships between miRNAs and cardiac
fibrosis. However, some meta-analyses have established relationships between miRNAs
and other diseases. Diagnostic performance of circulating miR-122 was evaluated for hep-
atocellular carcinoma using 13 studies with data for over 900 patients and 1200 controls
[219]. 37 studies of miRNA expression profiles and 6 studies of diagnostic accuracy were
used to identify miR-34a, miR-122 and miR-192, as potential diagnostic markers of non-
alcoholic fatty liver and non-alcoholic steatohepatitis diseases [220]. 7 highly significant
and consistently dysregulated miRNAs were identified in 20 studies of renal fibrosis [221].
6 out of these 7 miRNAs have been analysed in over 20 experiments of cardiac fibrosis
(Table 2.2). 5 of these miRNAs are consistently correlated with cardiac fibrosis according
to scoring models but only 2 miRNAs are present in the list of our 10 miRNAs selected
for downregulating cardiac fibrosis (Table 2.5). Other miRNAs were excluded based either
on their inconsistent correlation with cardiac fibrosis or during computational screening
for best correlated miRNAs with cardiac fibrosis. For future studies, a combination of
computational analysis and biological reasoning for miRNA selection might yield more
comprehensive results. Anyhow, the presence of overlapping miRNAs indicates that a few
common miRNAs might be responsible for causing renal and cardiac fibrosis.
This meta-analysis has some limitations. Although PubMed is huge database with qual-
ity control and in maintained by National Institutes of Health (NIH), other databases like
Embase and Web of Science can be explored for additional articles. Publications in other
languages can be translated. miRNAs have synergistic effect, that is, one miRNA targets
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multiple genes and affects many biological pathways [222]. miRNAs that downregulate
cardiac fibrosis might disturb the synergistic network and cause another disease. Hence, a
broader analysis, considering a wide array of diseases is required. For future studies, ma-
chine learning methods like Random Forest can be tested for miRNA selection. Random
forests can be used for classification and regression analysis and trains a combination of
decision trees, and then mode or mean of decision tree results can be used for prediction.
PLSR and Random Forest have been used together in publications to get better insights into
variables’ importance in the model. In comparison to linear models, Random Forest models
have sometimes shown better predictability [223, 224, 225]. More scoring models can be
explored, for example, for under-studied miRNAs, the penalty on number of experiments
can be increased by squaring the multiplication factor. Other combinations of mathematical
manipulations with biological reasons can be used to conduct this meta-analysis from an-
other perspective. To account for the synergistic effect of miRNAs, a tool can be developed
that uses the data aggregated in this meta-analysis and existing miRNA-mRNA interaction
data to provide a detailed report on miRNAs’ roles in biological pathways, with a focus on
cardiac fibrosis. Fibrosis in several organs like lung, liver and kidney can be investigated.
This meta-analysis concluded that downregulation of miR-21, miR-33, miR-125b, miR-
155-5p, miR-34a and upregulation of miR-29b, miR-29a, miR-26a, miR-30c, miR-29c can
downregulate cardiac fibrosis. Literature analysis validated the meta-analysis results and
it is proposed that under-studied miRNAs, like miR-33 and miR-122, should be analyzed
more for their roles in cardiac fibrosis. Computational models were made to predict car-
diac fibrosis using miRNA fold-changes as inputs. The fold-change dataset from this meta-
analysis can be used to establish relationships between any set of miRNAs and cardiac
fibrosis, and to predict the extent of cardiac fibrosis when exosomes with custom-designed
packages of miRNAs will be injected into animal models.
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CHAPTER 3
CONCLUSIONS AND FUTURE WORK
Stem/progenitor cell-based therapies can greatly impact the field of regenerative medicine
and have attracted researchers’ attention due to their efficacy in treating diseases in preclin-
ical transplantation, tissue injury models and human clinical trials. Experimental studies
have shown that exosomes secreted from stem cells have a significant role in the paracrine
signaling of transplanted stem cells. Along with lipids, proteins, and nucleic acids, miRNAs
are packaged inside exosomes and transported from stem cell to recipient cell for gene ex-
pression regulation in the recipient cell. Prior research suggests that miRNAs play a role
in determining the reparative effect of exosomes, and exosomes are instrumental to the
therapeutic effect of stem cells.
Cardiac fibrosis is characterized by an imbalance in ECM production and degradation,
resulting in accumulation of proteins in cardiac interstitium, causing cardiac dysfunction in
a wide array of cardiac diseases. Injury to heart can activate fibrotic responses, distorting
heart’s shape and compromising physiological cardiac functions. The reparative effects of
cardiac progenitor cells-derived exosomal miRNAs are being explored on cardiac fibrosis.
As a part of the Platt-Davis lab collaboration, our groups have been exploring methods for
treating myocardium post injury- decreasing myocardial fibrosis, increasing angiogenesis
in the damaged area, increasing proliferation of cardiac progenitor cells, etc. miRNAs and
exosomes are studied for identifying therapeutic RNA clusters in human cardiac progenitor
cells, engineering exosome like vesicles and evaluating effects of exosome delivery on heart
function and regeneration. With the knowledge of miRNAs that can downregulate cardiac
fibrosis, exosome therapy can be explored as a potential treatment- candidate miRNAs can
be packaged inside exosomes and injected for alleviating cardiac fibrosis.
There are over 900 publications that have studied the relationships between miRNAs
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and fibrosis markers in the heart. Using these publications and computational modeling,
this research was aimed at finding miRNAs that can downregulate cardiac fibrosis, iden-
tifying under-studied miRNAs that might be important regulators of cardiac fibrosis and
predicting cardiac fibrosis using miRNA inputs. Another goal was to develop a computa-
tional workflow that will allow us to analyze relationships between a set of chosen miRNAs
and cardiac fibrosis, and eventually to predict cardiac fibrosis given the input data for the
set of chosen miRNAs.
In summary, this meta-analysis identified 10 miRNAs that can downregulate cardiac
fibrosis. It was proposed that under-studied miRNAs, like miR-33 and miR-122, should be
analyzed more for their roles in cardiac fibrosis. Computational models were made to pre-
dict cardiac fibrosis using miRNA fold-changes as inputs. Using the fold-change dataset
from this meta-analysis, a computational workflow has been developed to establish rela-
tionships between any set of miRNAs and cardiac fibrosis, and to predict cardiac fibrosis
given the input data for the set of chosen miRNAs. This analysis consolidates relationships
between selected miRNAs and cardiac fibrosis and can be used to inform experimental
studies of cardiac remodeling.
Cardiac fibrosis can be caused due to a variety of reasons like myocardial infarction,
diabetes, atherosclerosis, to name a few. The articles included in this meta-analysis covered
many causes of cardiac fibrosis and therefore, the conclusions of this meta-analysis are
applicable to cardiac fibrosis in general. To the best of my knowledge, no one has published
such a comprehensive analysis of the relationships between miRNAs and cardiac fibrosis.
The miRNAs that have been identified to downregulate cardiac fibrosis in this meta-analysis
can be used to downregulate cardiac fibrosis, independent of its cause. For experiments
targeted at finding more miRNAs that can be used for decreasing cardiac fibrosis, the list
of under-studied miRNAs with cardiac-fibrosis related gene targets can be useful. The
extent of decrease in cardiac fibrosis can be predicted using the developed computational
workflow, if miRNA fold change data is available. If some correlation can be made between
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the amount of miRNA mimic or inhibitor that is supplied within the injected exosome
and their expression in target tissues, the prediction workflow developed in this research
can be used to fine tune the miRNA concentration needed to achieve the desired cardiac
fibrosis outcome. This would save time and resources of the experimentalists. This kind
of generalised prediction of cardiac fibrosis markers is possible only because in this meta-
analysis huge amounts of data was taken from approximately 250 publications studying
cardiac fibrosis.
Synergistic effect of miRNAs has not been considered in this analysis and might be
a challenge while conducting experiments. One miRNA has multiple mRNA targets, and
thereby one miRNA can be involved in many biological processes. miR-34a was identified
as profibrotic miRNA in this study. It has been reported that miR-34a decreases angiogene-
sis and causes cellular senescence in endothelial progenitor cells [226]. So, downregulation
of miR-34a has several simultaneous benefits: decrease cardiac fibrosis, increase angiogen-
esis, and inhibit cellular senescence. The profibrotic miRNA, miR-21, has been shown to
prevent cardiomyocytes apoptosis under oxidative stress [227]. In a case of cardiac injury,
upregulation of miR-21 to decrease cardiomyocyte apoptosis can in-turn increase cardiac
fibrosis, leading to impaired cardiac functions. Similarly, miR-29 family has been identified
as antifibrotic in this analysis, but upregulation of miR-29 family has been shown to cause
apoptosis in hearts post ischemia/reperfusion injury [228]. mRNA targets of the selected
miRNAs should be studied and pathway analysis should be performed to have a compre-
hensive outlook of the advantageous and disadvantageous effects of altering the expression
levels of miRNAs to decrease cardiac fibrosis. Further analysis should be performed to
study the synergistic effect of cardiac fibrosis-related miRNAs on other biological path-
ways. Therefore, there is a need to develop a platform that can inform researchers about
the potential side-effects of using a miRNA to regulate a particular biological process.
An all-encompassing tool can be developed to evaluate the roles of cardiac fibrosis-
related miRNAs in other biological pathways. The aggregated data from this analysis,
51
existing information on miRNA-mRNA interactions and their roles in biological pathways
can be taken from online databases to get comprehensive insights into other biological
outcomes like angiogenesis, migration, proliferation, along with cardiac fibrosis. When
changing miRNA levels for decreasing cardiac fibrosis, such an analysis would help in
accessing the effect of modified miRNA level on other biological pathways as well. The
computational workflow for analyzing relationships between chosen miRNA expression
levels and cardiac fibrosis, explained in the previous section can be automated. Query
pipeline can be developed to find mRNA targets and target pathways from online resources
for the chosen miRNAs. This tool can be manually updated by adding the extracted data
from recently published articles to the uploaded meta-analysis data. This tool would be
beneficial in understanding the impact of changing miRNA levels on cardiac fibrosis, their
effect on other pathways, and ultimately help researchers in making informed decisions
while designing experiments for improving heart functions post injury.
The results of this research can be used to inform experimental studies of cardiac re-
modeling. Exosomes can be engineered and injected to decrease cardiac fibrosis- agomirs
of antifibrotic miRNAs and antagomirs of profibrotic miRNAs identified in this meta-
analysis, can be transfected into exosomes. The computational workflow developed in this
thesis can be used to predict the extent of cardiac fibrosis when engineered exosomes with
custom-designed packages of miRNA content will be injected into animal models. Such
experiments can be explored to develop potential therapeutic options for cardiac fibrosis.
If this meta-analysis is extended for other organs, and some miRNAs are identified that can
downregulate fibrosis independent of the target organ, antifibrotic synthetic exosomes can






Python scripts written for data extraction and score calculation are shown below.
‘miRColumns’ should be replaced by the number of miRNAs in the aggregated data.
1. Concatenate fold-change and p-value data extracted from graphs, tables, and ex-
pression array, into one data sheet
# import packages
import pandas as pd
### concatenate fold-change data





# concatenate the fold-change data and save
df_FC = pd.concat([Study1, Study2, Study3], axis=0, join=’outer’,
ignore_index=True, sort=False)
df_FC.to_excel(’ConcatenatedSheet_FC.xlsx’)
### concatenate p-value data






# concatenate the p-value data and save
df_Pval = pd.concat([Study4, Study5, Study6], axis=0, join=’outer’,
ignore_index=True, sort=False)
df_Pval.to_excel(’ConcatenatedSheet_Pval.xlsx’)
2. Calculate scores from fold-change and p-value data for scoring model 1
2.1 Score Formula 1
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values



























# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM1_Score1.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
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2.2 Score Formula 2
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values



























# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM1_Score2.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
2.3 Find common miRNAs between scoring formulae
# import packages
import numpy as np
import pandas as pd




for currSet in arr[1:]:
result.intersection_update(currSet)
return list(result)
# In score excel sheets, sort miRNAs in decreasing order of their
absolute values



















FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_pos = FC[FC.columns.intersection(res_all)]




FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_neg = FC[FC.columns.intersection(nres_all)]
# save data of overlapping miRNAs
writer = pd.ExcelWriter(’SM1_DataTop200.xlsx’, engine=’xlsxwriter’)
data_pos.to_excel(writer, sheet_name = ’positive’)
data_neg.to_excel(writer, sheet_name = ’negative’)
writer.save()
3. Calculate scores from fold-change and p-value data for scoring model 2
3.1 Score Formula 1
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
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Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns















# calculating scoring values





























for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}











# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM2_Score1.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
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df.to_excel(writer, sheet_name = ’negative’)
writer.save()
3.2 Score Formula 2
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values




























for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}












# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM2_Score2.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
3.3 Score Formula 3
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
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# select miRNA and fibrosis columns















# calculating scoring values




























for key in points_pos.keys():
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if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}











# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM2_Score3.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
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writer.save()
3.4 Score Formula 4
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values




























for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}












# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM2_Score4.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
3.5 Find common miRNAs between scoring formulae
# import packages
import numpy as np
import pandas as pd
# Function to find common elements in arrays
def commonElements(arr):
result = set(arr[0])




# In score excel sheets, sort miRNAs in decreasing order of their
absolute values




















































FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_pos = FC[FC.columns.intersection(res_all)]

























FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_neg = FC[FC.columns.intersection(nres_all)]
# save data of overlapping miRNAs
writer = pd.ExcelWriter(’SM2_DataTop200.xlsx’, engine=’xlsxwriter’)
data_pos.to_excel(writer, sheet_name = ’positive’)
data_neg.to_excel(writer, sheet_name = ’negative’)
writer.save()
4. Calculate scores from fold-change and p-value data for scoring model 3
4.1 Score Formula 1
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values




























for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():















# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM3_Score1.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
4.2 Score Formula 2
# import packages
from scipy import stats
import numpy as np
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import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns















# calculating scoring values
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for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}











# save miRNAs with positive and negative correlation values with
fibrosis markers separately
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writer = pd.ExcelWriter(’SM3_Score2.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
4.3 Score Formula 3
# import packages
from scipy import stats
import numpy as np
import pandas as pd
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns
















# calculating scoring values




























for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}












# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM3_Score3.xlsx’, engine=’xlsxwriter’)
df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
4.4 Score Formula 4
# import packages
from scipy import stats
import numpy as np
import pandas as pd
90
# convert fibrosis data into one column using vertical concatenation
in both fold-change and p-value data sheet
# load fold-change and p-value data
FC = pd.read_excel(Fold-change file,sheet_name=’Log base 2’)
Pval = pd.read_excel(P-value file,sheet_name=’Sheet1’)
# select miRNA and fibrosis columns















# calculating scoring values
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for key in points_pos.keys():
if max_num < points_pos[key]:
max_num = points_pos[key]
for key in points_neg.keys():
if max_num < points_neg[key]:
max_num = points_neg[key]
correlation_norm_pos = {}











# save miRNAs with positive and negative correlation values with
fibrosis markers separately
writer = pd.ExcelWriter(’SM3_Score4.xlsx’, engine=’xlsxwriter’)
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df = pd.DataFrame.from_dict(correlation_pos, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’positive’)
df = pd.DataFrame.from_dict(correlation_neg, orient=’index’,
columns=[’Fibrosis’])
df.to_excel(writer, sheet_name = ’negative’)
writer.save()
4.5 Find common miRNAs between scoring formulae
# import packages
import numpy as np
import pandas as pd
# Function to find common elements in arrays
def commonElements(arr):
result = set(arr[0])
for currSet in arr[1:]:
result.intersection_update(currSet)
return list(result)
# In score excel sheets, sort miRNAs in decreasing order of their
absolute values




















































FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_pos = FC[FC.columns.intersection(res_all)]

























FC = pd.read_excel(Fold-change sheet,sheet_name=’Log base 2’)
data_neg = FC[FC.columns.intersection(nres_all)]
# save data of overlapping miRNAs
writer = pd.ExcelWriter(’SM3_DataTop200.xlsx’, engine=’xlsxwriter’)
data_pos.to_excel(writer, sheet_name = ’positive’)
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non-alcoholic fatty liver disease: A systematic review and meta-analysis,” Journal
of hepatology, vol. 69, no. 6, pp. 1335–1348, 2018.
[221] A. Gholaminejad, H. Abdul Tehrani, and M. Gholami Fesharaki, “Identification
of candidate microrna biomarkers in renal fibrosis: A meta-analysis of profiling
studies,” Biomarkers, vol. 23, no. 8, pp. 713–724, 2018.
[222] X. Chen, W. Zhao, Y. Yuan, Y. Bai, Y. Sun, W. Zhu, and Z. Du, “Micrornas tend
to synergistically control expression of genes encoding extensively-expressed pro-
teins in humans,” PeerJ, vol. 5, e3682, 2017.
[223] Z. Hao, J. Du, B. Nie, F. Yu, R. Yu, and W. Xiong, “Random forest regression based
on partial least squares connect partial least squares and random forest,” in 2016
International Conference on Artificial Intelligence: Technologies and Applications,
Atlantis Press, 2016, pp. 191–196.
120
[224] N. Reddy, M. Gebreslasie, and R. Ismail, “A hybrid partial least squares and ran-
dom forest approach to modelling forest structural attributes using multispectral
remote sensing data,” South African Journal of Geomatics, vol. 6, no. 3, pp. 377–
394, 2017.
[225] E. Vigneau, P. Courcoux, R. Symoneaux, L. Guérin, and A. Villière, “Random
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